Skip to content

Hair Benefit Study For The Test Products

To evaluate the Anti-dandruff efficacy of test products in healthy Indian human - None

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/09/036928
Enrollment
220
Registered
2021-09-28
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Unilever Industries Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Female and male subjects in the ratio of 2:1 in general good health. 2.Subjects in the age group 18-42 years (both the ages inclusive). 3.Subjects willing to give a written informed consent and agree to come for a regular follow up visit. 4.Subjects willing to abide by and comply with the study protocol. 5.Subjects who have not participated in a similar investigation in the past three months. 6.Subjects who agree to refrain from using hair dye / hair colour /henna during the study period. 7.Subjects willing to refrain from any type of hair treatment like perming, straightening etc. during the study duration 8.Subjects who agree not to change their regular regimen (including hair oils)

Exclusion criteria

Exclusion criteria: 1.Subjects who have undergone hair growth treatment within 3 months before screening into the study. 2.Subjects having any active scalp disease which may interfere in the study ââ?¬â?? dermatologistââ?¬•s judgement. 3.Subjects (male) having androgenic alopecia, male pattern baldnessââ?¬• not be included in study. 4.Subjects who have taken chemotherapy for cancer in the 6 months prior to start of the study or have a plan to do treatments during study. 5.Subjects (females) who are pregnant or lactating 6.Subjects who have had hair transplant. 7.A known history or present condition of allergic response/hypersensitivity to any cosmetic ingredients and pharmaceutical products. 8.Chronic illness which may influence the cutaneous state. 9.Subjects participating in other similar cosmetic or therapeutic trial within last three months 10.Any history of underlying uncontrolled medical illness including diabetes mellitus, hypertension, HIV, hepatitis, severe anemia, serious disorder of heart and respiratory apparatus or any other serious medical illness. 11.Subjects (males) who are having androgenic alopecia, male pattern baldness.

Design outcomes

Primary

MeasureTime frame
Significant improvement in dandruff condition by expert/dermatologist assessmentTimepoint: 4 weeks product and 2 weeks regression

Secondary

MeasureTime frame
Significant reduction and prevention of dandruff associated conditions by expert/dermatologist assessmentTimepoint: 4 weeks product and 2 weeks regression

Countries

India

Contacts

Public ContactSudhanthiran S

MS Clinical Research Pvt Ltd

ritambhara@mscr.in08041125934

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026